Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine.

作者: Weilian Yang , Rolf F. Barth , Joan H. Rotaru , Melvin L. Moeschberger , Darrel D. Joel

DOI: 10.1023/A:1005769214899

关键词: ChemistryMannitolNuclear medicineEndocrinologyInternal medicineBlood–brain barrierRadiation therapyCentral nervous system diseasePharmacokineticsBiodistributionGliomaBoron

摘要: Boronophenylalanine (BPA) has been used for boron neutron capture therapy (BNCT) of brain tumors in both experimental animals and humans. The purpose the present study was to determine if efficacy BNCT could be enhanced by means intracarotid (i.c.) injection BPA with or without blood-brain barrier disruption (BBB-D) irradiation using a rat tumor model. For biodistribution studies, F98 glioma cells were implanted stereotactically into brains Fischer rats, and12 days later BBB-D carried out i.c. infusion 25% mannitol (1.373 mOsmol/ml), followed immediately administration 300, 500 800 mg BPA/kg body weight (b.w.). At dose fourfold increase concentration (94.5 μg/g) seen at 2.5 hours after BBB-D, compared 20.8 μg/g i.v. injected animals. best composite normal tissue ratios observed which time tumor: blood (T: Bl) ratio was10.9, Br) 7.5, 3.2 5.0 respectively rats. In contrast, that had received T: Bl Br 8.5 5.9, respectively, 42.7μg/g. experiments, initiated 14 intracerebral implantation cells, mg/kg b.w. administered irradiated hourslater Brookhaven Medical Research Reactor collimated beam thermal neutrons delivered head. mean survival untreated control rats 24 ± 3 days, 30 2 controls, 37 those receiving BPA, 52 15 95 BNCT. latter group 246% life span (ILS) controls 124% ILS These data are ever obtained model suggest may useful as

参考文章(55)
Reinhard A. Gahbauer, Ralph G. Fairchild, Joseph H. Goodman, Thomas E. Blue, RBE in Normal Tissue Studies Springer US. pp. 123- 128 ,(1992) , 10.1007/978-1-4615-3408-2_14
Y Mori, T Kobayashi, C Honda, Y Mishima, K Yoshino, K Kanda, H Kakihana, A Suzuki, Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlentherapie Und Onkologie. ,vol. 165, pp. 127- 129 ,(1989)
D D Bigner, N A Vick, J M Fischer, D R Groothuis, Comparative permeability of different glioma models to horseradish peroxidase. Cancer treatment reports. pp. 13- 18 ,(1981)
Y. Mishima, C. Honda, M. Ichihashi, M. Shiono, N. Wadabayashi, H. Obara, J. Hiratsuka, H. Fukuda, H. Karashima, K. Kanda, T. Kobayashi, K. Yoshino, Selective Melanoma Thermal Neutron Capture Therapy for Lymph Node Metastases Advances in Neutron Capture Therapy. pp. 705- 710 ,(1993) , 10.1007/978-1-4615-2978-1_140
Otto K. Harling, Robert G. Zamenhof, John A. Bernard, "Neutron Beam Design, Development, and Performance for Neutron Capture Therapy" ,(2012)
Charles G. Orosz, Steven M. James, Rolf F. Barth, Jone-Jiun Tzeng, Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Research. ,vol. 51, pp. 2373- 2378 ,(1991)
Darell D. Bigner, Dennis E. Bullard, Sandra H. Bigner, Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Research. ,vol. 45, pp. 5240- 5245 ,(1985)
R. Bergland, E. Elowitz, J. A. Coderre, D. Joel, M. Chadha, A Phase 1 Trial of Intravenous Boronophenylalanine-Fructose Complex in Patients with Glioblastoma Multiforme 6. international symposium on neutron capture therapy for cancer, Kobe (Japan), 31 Oct - 4 Nov 1994. pp. 739- 745 ,(1996) , 10.1007/978-1-4757-9567-7_105
McLendon Re, Bigner Dd, Fuchs He, Archer Ge, Colvin Om, Schuster Jm, Friedman Hs, Intraarterial Therapy of Human Glioma Xenografts in Athymic Rats Using 4-Hydroperoxycyclophosphamide Cancer Research. ,vol. 53, pp. 2338- 2343 ,(1993)
Paul L. Kornblith, Michael Walker, Chemotherapy for malignant gliomas. Journal of Neurosurgery. ,vol. 68, pp. 1- 17 ,(1988) , 10.3171/JNS.1988.68.1.0001